Glenmark Pharmaceuticals (NSE:GLENMARK) Cash-to-Debt : 1.15 (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Glenmark Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2024 was 1.15.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Glenmark Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Glenmark Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

NSE:GLENMARK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2 Med: 0.31 Max: 1.36
Current: 1.15

During the past 13 years, Glenmark Pharmaceuticals's highest Cash to Debt Ratio was 1.36. The lowest was 0.20. And the median was 0.31.

NSE:GLENMARK's Cash-to-Debt is ranked better than
53.23% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs NSE:GLENMARK: 1.15

Glenmark Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Glenmark Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Glenmark Pharmaceuticals Cash-to-Debt Chart

Glenmark Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

0.23

0.24

0.36

0.26

1.36

Glenmark Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															0.26	N/A	1.36	N/A	1.15

Competitive Comparison of Glenmark Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Glenmark Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Cash-to-Debt falls into.

Glenmark Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Glenmark Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	16704.01	/	(10792.39	+	1516.91)
	=	1.36

Glenmark Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	20406.98	/	(16408.25	+	1400.24)
	=	1.15

Glenmark Pharmaceuticals (NSE:GLENMARK) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Glenmark Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Glenmark Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » Cash-to-Debt

Traded in Other Exchanges

532296:India

Address

B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099

Website

https://www.glenmarkpharma.com

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe, and the rest of the world.

Glenmark Pharmaceuticals Headlines

No Headlines